Search
Searching Content indexed under Litigation, Mediation & Arbitration by David Torchetti ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
PMPRB Decision Creates Uncertainty For Patentees
On September 27, 2017, a two-member Hearing Panel of the Patented Medicine Price Review Board (PMPRB) ruled that the ultra-rare disease drug Soliris® (eculizumab), manufactured by Alexion Pharmaceuticals Inc. (Alexion), was "excessively priced." The Panel ordered both a reduction of the price of Soliris going forward and required Alexion to pay past "excessive" revenues.
Canada
8 Nov 2017
Links to Result pages
 
1